(OGN) Organon - Ratings and Ratios
Contraception, Fertility, Biosimilars, Cholesterol, Respiratory, Dermatology
OGN EPS (Earnings per Share)
OGN Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 66.4% |
| Value at Risk 5%th | 99.8% |
| Relative Tail Risk | -8.59% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.91 |
| Alpha | -63.69 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.514 |
| Beta | 0.917 |
| Beta Downside | 0.949 |
| Drawdowns 3y | |
|---|---|
| Max DD | 77.17% |
| Mean DD | 41.07% |
| Median DD | 40.00% |
Description: OGN Organon November 09, 2025
Organon & Co. (NYSE: OGN) is a globally diversified health-solutions company that markets prescription drugs and medical devices across the United States, Europe, Canada, Japan, the broader Asia-Pacific, Latin America, the Middle East, Russia, and Africa. The firm’s legacy dates back to 1923 and its headquarters are in Jersey City, New Jersey.
Its core strength lies in women’s health, where it offers a full spectrum of contraceptive and fertility products-including the long-acting Nexplanon implant, the NuvaRing vaginal ring, daily oral pills (Cerazette, Marvelon, Mercilon), and assisted-reproduction agents such as Follistim AQ, Elonva, and Ganirelix. In 2024, the women’s-health segment contributed roughly 38 % of total sales and grew at a 12 % year-over-year rate, driven by rising demand for reversible contraception and expanding fertility services.
Organon’s biosimilars portfolio targets high-growth immunology and oncology markets with products like Brenzys, Renflexis, Hadlima, Ontruzant, and Aybintio. The company expects to launch three additional biosimilars by 2025, which should add an incremental $250 million in revenue, assuming a 15 % market-share capture in each therapeutic area.
Beyond women’s health and biosimilars, Organon sells a broad range of established brands: cholesterol-lowering agents (Zetia, Vytorin, Zocor), antihypertensives (Cozaar, Hyzaar), respiratory and allergy treatments (Singulair, Nasonex, Asmanex), dermatology (Elocon, Diprosone), bone health (Fosamax), non-opioid pain (Arcoxia), and urology/hair-loss drugs (Proscar, Propecia). These legacy products generate stable cash flow, with the cardiovascular and respiratory segments together representing about 22 % of total revenue.
The company distributes its products through a mix of drug wholesalers, retail pharmacies, hospitals, health-maintenance organizations, pharmacy-benefit managers, and government programs, giving it exposure to both commercial and payer-driven pricing dynamics.
Key macro-drivers for Organon include an aging global population that fuels demand for chronic-disease therapies, a sustained increase in women’s-health spending (projected CAGR ≈ 7 % through 2028), and the accelerating adoption of biosimilars as cost-containment tools in major markets.
For a deeper quantitative assessment of OGN’s valuation and risk profile, the ValueRay platform offers a data-rich dashboard worth exploring.
OGN Stock Overview
| Market Cap in USD | 1,981m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2021-06-02 |
| Return 12m vs S&P 500 | -55.9% |
| Analyst Rating | 3.0 of 5 |
OGN Dividends
| Dividend Yield | 4.25% |
| Yield on Cost 5y | 1.17% |
| Yield CAGR 5y | 25.99% |
| Payout Consistency | 98.0% |
| Payout Ratio | 8.7% |
OGN Growth Ratios
| CAGR 3y | -29.32% |
| CAGR/Max DD Calmar Ratio | -0.38 |
| CAGR/Mean DD Pain Ratio | -0.71 |
| Current Volume | 6255.5k |
| Average Volume | 6310.8k |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (501.0m TTM) > 0 and > 6% of Revenue (6% = 378.1m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA -1.01pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 32.07% (prev 30.68%; Δ 1.40pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 949.0m > Net Income 501.0m (YES >=105%, WARN >=100%) |
| Net Debt (8.16b) to EBITDA (1.57b) ratio: 5.18 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.75 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (260.7m) change vs 12m ago 0.34% (target <= -2.0% for YES) |
| Gross Margin 55.04% (prev 58.26%; Δ -3.22pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 47.91% (prev 50.26%; Δ -2.35pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.37 (EBITDA TTM 1.57b / Interest Expense TTM 516.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.98
| (A) 0.15 = (Total Current Assets 4.70b - Total Current Liabilities 2.68b) / Total Assets 13.55b |
| (B) 0.10 = Retained Earnings (Balance) 1.32b / Total Assets 13.55b |
| (C) 0.09 = EBIT TTM 1.22b / Avg Total Assets 13.15b |
| (D) 0.06 = Book Value of Equity 747.0m / Total Liabilities 12.65b |
| Total Rating: 1.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 60.94
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield 5.58% = 2.79 |
| 3. FCF Margin 8.98% = 2.25 |
| 4. Debt/Equity 9.74 = -2.50 |
| 5. Debt/Ebitda 5.18 = -2.50 |
| 6. ROIC - WACC (= 5.91)% = 7.39 |
| 7. RoE 75.54% = 2.50 |
| 8. Rev. Trend 39.99% = 3.00 |
| 9. EPS Trend 0.28% = 0.01 |
What is the price of OGN shares?
Over the past week, the price has changed by -2.33%, over one month by -19.72%, over three months by -18.86% and over the past year by -48.99%.
Is Organon a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of OGN is around 5.65 USD . This means that OGN is currently overvalued and has a potential downside of -24.97%.
Is OGN a buy, sell or hold?
- Strong Buy: 0
- Buy: 2
- Hold: 3
- Sell: 2
- Strong Sell: 0
What are the forecasts/targets for the OGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.7 | 28.4% |
| Analysts Target Price | 9.7 | 28.4% |
| ValueRay Target Price | 6 | -20.8% |
OGN Fundamental Data Overview November 17, 2025
P/E Trailing = 3.9424
P/E Forward = 5.0302
P/S = 0.3144
P/B = 2.1608
Beta = 0.554
Revenue TTM = 6.30b USD
EBIT TTM = 1.22b USD
EBITDA TTM = 1.57b USD
Long Term Debt = 8.78b USD (from longTermDebt, last quarter)
Short Term Debt = 45.0m USD (from shortTermDebt, last quarter)
Debt = 8.83b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.16b USD (from netDebt column, last quarter)
Enterprise Value = 10.14b USD (1.98b + Debt 8.83b - CCE 672.0m)
Interest Coverage Ratio = 2.37 (Ebit TTM 1.22b / Interest Expense TTM 516.0m)
FCF Yield = 5.58% (FCF TTM 566.0m / Enterprise Value 10.14b)
FCF Margin = 8.98% (FCF TTM 566.0m / Revenue TTM 6.30b)
Net Margin = 7.95% (Net Income TTM 501.0m / Revenue TTM 6.30b)
Gross Margin = 55.04% ((Revenue TTM 6.30b - Cost of Revenue TTM 2.83b) / Revenue TTM)
Gross Margin QoQ = 53.50% (prev 54.83%)
Tobins Q-Ratio = 0.75 (Enterprise Value 10.14b / Total Assets 13.55b)
Interest Expense / Debt = 1.45% (Interest Expense 128.0m / Debt 8.83b)
Taxrate = 34.16% (83.0m / 243.0m)
NOPAT = 804.0m (EBIT 1.22b * (1 - 34.16%))
Current Ratio = 1.75 (Total Current Assets 4.70b / Total Current Liabilities 2.68b)
Debt / Equity = 9.74 (Debt 8.83b / totalStockholderEquity, last quarter 906.0m)
Debt / EBITDA = 5.18 (Net Debt 8.16b / EBITDA 1.57b)
Debt / FCF = 14.41 (Net Debt 8.16b / FCF TTM 566.0m)
Total Stockholder Equity = 663.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.70% (Net Income 501.0m / Total Assets 13.55b)
RoE = 75.54% (Net Income TTM 501.0m / Total Stockholder Equity 663.2m)
RoCE = 12.93% (EBIT 1.22b / Capital Employed (Equity 663.2m + L.T.Debt 8.78b))
RoIC = 8.42% (NOPAT 804.0m / Invested Capital 9.55b)
WACC = 2.50% (E(1.98b)/V(10.81b) * Re(9.39%) + D(8.83b)/V(10.81b) * Rd(1.45%) * (1-Tc(0.34)))
Discount Rate = 9.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.79%
[DCF Debug] Terminal Value 74.24% ; FCFE base≈604.0m ; Y1≈631.0m ; Y5≈730.6m
Fair Price DCF = 38.95 (DCF Value 10.13b / Shares Outstanding 260.0m; 5y FCF grow 4.76% → 3.0% )
EPS Correlation: 0.28 | EPS CAGR: 8.36% | SUE: 0.64 | # QB: 0
Revenue Correlation: 39.99 | Revenue CAGR: 2.80% | SUE: 0.72 | # QB: 0
Additional Sources for OGN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle